Advertisement
Singapore markets closed
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Bitcoin USD

    60,259.12
    -1,170.19 (-1.90%)
     
  • CMC Crypto 200

    1,258.05
    -25.78 (-1.97%)
     
  • S&P 500

    5,470.95
    -11.92 (-0.22%)
     
  • Dow

    39,073.07
    -90.99 (-0.23%)
     
  • Nasdaq

    17,806.40
    -52.28 (-0.29%)
     
  • Gold

    2,333.90
    -2.70 (-0.12%)
     
  • Crude Oil

    81.38
    -0.36 (-0.44%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock

We recently published a list of 7 lesser-known, under-the-radar AI stocks hedge funds are piling into. Since RXRX is part of the list, the stock deserves a deeper look.

Recursion Pharmaceuticals is an NVIDIA Corp (NASDAQ:NVDA) partner that will use the semiconductor giant's chips and technology for drug discovery. The NVIDIA Corp (NASDAQ:NVDA) "effect" is now causing many stocks to create buzz in the market, while many analysts believe NVDA shares themselves are overvalued. If you are looking for an AI stock that is as promising as NVIDIA Corp (NASDAQ:NVDA) but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

The AI-led stock rally that rewarded mega-cap technology stocks has finally started to trickle down to other industry players that were seemingly not related to the AI and tech industry. Consider this: The information technology sector gained about 11% over the past three months, while the S&P 500 utilities sector jumped 18% in the same period. Why? Because investors are scrambling to pile into utilities since they are set to benefit from the dramatic rise in power demand thanks to the data center boom caused by the mass AI adaption. As Nvidia's CEO Jensen Huang put it in the company's latest earnings call, the "next industrial revolution" has started with the dawn of AI and across the globe data centers are being "converted into AI factories."

A Wall Street Journal report recently quoted Nadia Lovell, senior U.S. equity strategist, global wealth management at UBS, who said that the market is "no longer dependent on just one stock" when it comes to AI as she sees a "broadening out of the AI trade."

ADVERTISEMENT

Insider Monkey's research backs this notion. Our research recently unlocked several AI stocks that are better than mega-cap AI stocks with soaring valuations. If you are looking for an AI stock that is as promising as Microsoft but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

For this article we first conducted thorough research to see which lesser-known companies are offering products and services set to see demand in the AI revolution. These companies included firms making hardware, software, infrastructure and backend products necessary for mass AI deployment and consumption. From these companies we chose 7 stocks with the highest number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Photo by Austin Distel on Unsplash

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)

Number of Hedge Fund Investors: 21

AI-based drug discovery is one of the biggest trends major companies and venture capitalists are betting on. Some estimates suggest AI-led drug discovery could soon be a $100 billion business. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is an AI drug discovery play, as Recursion Pharmaceuticals Inc (NASDAQ:RXRX) uses high-dimensional data and predictive results for drug discovery and development. Last year, Nvidia decided to invest $50 million in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) in a partnership that would see the combination of Recursion Pharmaceuticals Inc's (NASDAQ:RXRX) chemical and biological datasets with NVIDIA DGX™ Cloud and other AI tech stack for drug discovery.

As of the end of the first quarter of 2024, 21 hedge funds tracked by Insider Monkey reported owning stakes in Recursion Pharmaceuticals Inc (NASDAQ:RXRX). The biggest stakeholder of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) during this period was Catherine D. Wood's ARK Investment Management which had a $245 million stake in Recursion Pharmaceuticals Inc (NASDAQ:RXRX).

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) ranks 6th in Insider Monkey’s list of the 7 Best Under-The-Radar AI Stocks Hedge Funds are Buying.

If you are looking for an AI stock that is as promising as Microsoft but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: Michael Burry Is Selling These Stocks and Jim Cramer is Recommending These Stocks.

Disclosure: None. This article is originally published at Insider Monkey.